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Introduction
============

The COVID-19 pandemic placed an unprecedented and overwhelming burden on the U.S. healthcare system. Since the first case of COVID-19 in the U.S., there have been over two million COVID-19 cases and 122,000 deaths as of June 25, 2020 \[[@REF1]\]. One-third of these deaths are nursing home residents or workers \[[@REF2]\]. Data from small studies conducted in China \[[@REF3]\] and France \[[@REF4]\] present the clinical outcomes of COVID-19 patients who were treated with hydroxychloroquine (HCQ) and/or azithromycin (AZI). However, since HCQ and AZI are both cardiotoxic, there are concerns about the development of arrhythmia in patients treated with these drugs \[[@REF5]\]. With limited treatment options, our group first treated high-risk COVID-19 patients in long-term care facilities (LTCFs) with doxycycline (DOXY) and HCQ \[[@REF6]\]. DOXY has anti-inflammatory \[[@REF7]\], immunomodulating \[[@REF8]\], cardioprotective \[[@REF9]-[@REF10]\], and antiviral \[[@REF11]\] activities. Subsequently, other studies noted the harmful side effects and mortality associated with HCQ administration \[[@REF12]\].

Based on current evidence and reference articles that detail COVID-19 pathophysiology and DOXY\'s mechanisms of action, DOXY may be an effective drug in the treatment of COVID-19. As a result, we began treating high-risk patients with only DOXY and supportive care. The efficacy of early DOXY intervention in high-risk COVID-19 patients in LTCFs is unknown. In this observational study, we collected data retrospectively, and we are presenting our clinical observations and outcomes of DOXY for high-risk patients with moderate to severe COVID-19 infections in LTCFs.

Materials and methods
=====================

This case series assessed the clinical outcomes of eighty-nine (89) high-risk patients in LTCFs who developed a sudden onset of fever, cough, shortness of breath (SOB), and hypoxia between March 18 and May 13, 2020. High-risk patients were defined as patients who had at least one comorbidity such as hypertension (HTN), diabetes, coronary artery disease (CAD), congestive heart failure (CHF), chronic obstructive pulmonary disorder (COPD), obesity, or ventilator-dependency. These patients were diagnosed with COVID-19 and they were treated with an early course of DOXY (100 mg PO or IV for seven days) and regular standard of care. Since all patients were closely monitored by healthcare workers, COVID-19 symptoms were immediately noticed; DOXY was started within 12 hours and RT-PCR COVID-19 swab was collected. Assessed measures were patients' characteristics, fever, SOB, cough, oxygen saturation/pulse oximetry (POX), radiologic improvements, laboratory tests, DOXY side effects, hospital transfers, and death. Clinical recovery was defined as a resolution of fever, resolution of SOB, and improvement of POX (≥93%). Follow-up chest X-rays (CXR) were ordered if clinically indicated.

The statistical analysis was done using Microsoft Excel 2016 (Microsoft Corporation, Redmond, Washington) with statistical application packages and IBM SPSS v23 (IBM Corp., Armonk, NY). The two-tailed T-test was used for between-group intervals in parametric data (e.g. POX). Binary logistic analysis and regression were used to assess the association of risk factors with the outcome. The patients' outcomes were recorded 30 days after symptoms onset.

All patients or patients' families gave informed consent before DOXY treatment was started, and oversight medical boards and corporate clinical services approved this observational study.

Results
=======

Table [1](#TAB1){ref-type="table"} summarizes the characteristics, clinical features, lab and radiology results, outcomes, and side effects of DOXY of all 89 patients who were started with early DOXY treatment. The median age is 78 years, and the range is 43-101 years. One hundred percent (100%) of patients (n=89) tested positive for COVID-19 through reverse transcription-polymerase chain reaction (RT-PCR) and 85% of patients (n=76) showed clinical recovery. Eleven percent (11%) of patients died (n=10) and 3% of patients (n=3) were transferred to hospitals due to clinical deterioration.

###### Characteristics, clinical outcomes, clinical features, lab and radiology results, side effects of doxycycline, and other antibiotics of all 89 high-risk COVID-19 patients who started seven-day doxycycline treatment in long-term care facilities

\*Clinical recovery defined by resolution of fever (3.7 days), resolution of SOB (4.2 days), and average POX improvement 95%

\*\*Four percent (n=4) of ventilator-dependent patients recovered and the ventilator setting returned to baseline.

\*\*\*Chest X-ray not ordered, not required, or pending.

BUN: blood urea nitrogen; CRP: C-reactive protein; LFT: liver function test; LDH: lactate dehydrogenase; POX: pulse oximetry

  ---------------------------------------------- ----------------------- ------------
  Assessed Measures                              LTCF Residents (n=89)   Percentage
  Median Age, Years (Range)                      78 (43-101)              
  Male                                           50                      56%
  Female                                         39                      44%
  Clinically Recovered\*                         76                      85%
  Transferred to Hospital                        3                       3%
  Death                                          10                      11%
  Hypertension (HTN)                             62                      70%
  Diabetes                                       30                      34%
  Coronary Artery Disease (CAD)                  41                      46%
  Congestive Heart Failure (CHF)                 23                      26%
  Chronic Obstructive Pulmonary Disease (COPD)   31                      35%
  Obesity                                        37                      42%
  Ventilator Dependency\*\*                      4                       4%
  Fever                                          87                      98%
  Shortness of Breath (SOB)                      85                      96%
  Cough                                          83                      93%
  Malaise/Weakness                               71                      80%
  Altered Mental Status                          56                      63%
  Diarrhea                                       31                      35%
  Chest Pain                                     27                      30%
  Tested COVID-19 Positive via RT-PCR            89                      100%
  High BUN                                       50                      56%
  High CR                                        46                      52%
  High LFT                                       33                      37%
  High Regular CRP                               65                      73%
  High Ferritin                                  63                      71%
  High LDH                                       34                      38%
  High D-Dimer                                   57                      64%
  High Troponin                                  40                      45%
  High Procalcitonin                             34                      38%
  Chest X-Ray (CXR) with Pneumonia               85                      96%
  Chest X-Ray (CXR) Improved                     39                      44%
  Chest X-ray (CXR) Not Improved                 41                      46%
  Chest X-Ray (CXR) Unavailable\*\*\*            9                       10%
  Nausea, Vomiting, and Abdominal Discomfort      6                      7%
  No Side Effects                                83                      93%
  Other Antibiotics                              11                      12%
  ---------------------------------------------- ----------------------- ------------

Table [2](#TAB2){ref-type="table"} summarizes the characteristics, clinical features, lab and radiology results, outcomes, and side effects of DOXY of the remaining 76 patients who successfully completed the seven-day DOXY treatment. One hundred percent (100%) of patients demonstrated clinical improvement. After DOXY treatment started, resolution of fever and SOB occurred at an average of 3.7 days and 4.2 days, respectively. Average POX before and after treatment was 84% and 95%, respectively.

###### Characteristics, clinical outcomes, clinical features, lab and radiology results, side effects of doxycycline, and other antibiotics of 76 high-risk COVID-19 patients who completed seven-day doxycycline treatment in long-term care facilities

This table includes all patients who completed a full course (7 days) of DOXY therapy and excludes any patients who died and who were transferred to hospital and did not complete the seven-day course.

\*Clinical recovery defined by resolution of fever (3.7 days), resolution of SOB (4.2 days), and average POX improvement 95% after treatment.

\*\*Four percent (n=4) ventilator-dependent patients recovered and the ventilator setting returned to baseline.

\*\*\*Chest X-ray either not ordered, or not required or pending.

BUN: blood urea nitrogen; CRP: C-reactive protein; LFT: liver function test; LDH: lactate dehydrogenase; POX: pulse oximetry

  ---------------------------------------------------------------------------- ----------------------- ------------
  Assessed Measures                                                            LTCF Residents (n=76)   Percentage
  Median Age, Years (Range)                                                    79 (43-101)              
  Male                                                                         42                      55%
  Female                                                                       34                      45%
  Clinically Recovered\*                                                       76                      100%
  Hypertension (HTN)                                                           52                      68%
  Diabetes                                                                     25                      33%
  Coronary Artery Disease (CAD)                                                35                      46%
  Congestive Heart Failure (CHF)                                               19                      25%
  Chronic Obstructive Pulmonary Disease (COPD)                                 26                      34%
  Obesity                                                                      33                      43%
  Ventilator Dependency\*\*                                                    4                       4%
  Fever                                                                        74                      97%
  Shortness of Breath (SOB)                                                    72                      95%
  Cough                                                                        71                      93%
  Chest Pain                                                                   21                      28%
  Malaise/Weakness                                                             62                      82%
  Altered Mental Status                                                        45                      59%
  Diarrhea                                                                     25                      33%
  COVID-19 Positive                                                            76                      100%
  High BUN                                                                     39                      51%
  High CR                                                                      39                      51%
  High LFT                                                                     26                      34%
  High Regular CRP                                                             53                      70%
  High Ferritin                                                                53                      70%
  High LDH                                                                     27                      36%
  High D-Dimer                                                                 48                      63%
  High Troponin                                                                32                      42%
  High Procalcitonin                                                           28                      37%
  Individuals with Pulse Oximetry (POX) Between 60% and 69% Before Treatment   4                       5%
  Individuals with Pulse Oximetry (POX) Between 70% and 80% Before Treatment   18                      20%
  Individuals with Pulse Oximetry (POX) Between 81% and 89% Before Treatment   42                      47%
  Individuals with Pulse Oximetry (POX) Between 90% and 92% Before Treatment   25                      28%
  Average Pulse Oximetry (POX) After Treatment                                 76                      95%
  Chest X-Ray (CXR) with Pneumonia                                             72                      95%
  Chest X-Ray (CXR) Improved                                                   36                      47%
  Chest X-Ray (CXR) Not Improved                                               31                      41%
  Chest X-Ray (CXR) Unavailable\*\*\*                                          9                       12%
  Nausea, Vomiting and Abdominal Discomfort                                    6                       8%
  No Side Effects                                                              70                      92%
  Other Antibiotics                                                            6                       8%
  ---------------------------------------------------------------------------- ----------------------- ------------

There was a statistically significant difference in POX before (pre-POX) and after (post-POX) treatment (n = 89, 84.7 ± 7% vs. 95 ± 2.6%, p = 0.0001). In the multivariate analysis model, the resolution of fever was associated with a reduction in mortality (Coeff = -0.96, p = 0.0001). Higher pre-POX and post-POX were also associated with decreased mortality; lower pre- and post-treatment POX is associated with increased mortality (pre-oxygen saturation (Spo2) vs Death, Coeff = -0.01, p = 0.023; Post-spo2 vs Death, Coeff = -0.05, p = 0.0002). Other variables, such as initial CXR with pneumonia, BUN, creatinine, liver enzyme levels, CRP, ferritin, LDH, D-Dimer, troponin, and procalcitonin, were not associated with mortality. Overall mortality at 30 days in our cohort was 11% (n=10). Clinical improvement was noted in 76 patients. Additionally, 3% (n=3) required transfer to a hospital while the rest of the patients were treated in the nursing home facility.

Discussion
==========

COVID-19 is a positive-sense, single-stranded ribonucleic acid (RNA) virus \[[@REF13]\], with a lipophilic outer shell that allows the pathogen to easily infiltrate lung tissue \[[@REF14]\]. The coronavirus is believed to recognize and bind to cluster of differentiation 26 (CD26)/dipeptidyl peptidase-4 (DPP4) markers expressed on the cell surface, serving as an entry point for viral invasion \[[@REF15]\]. COVID-19 infects the upper and lower respiratory tract, causing the release of pro-inflammatory cytokines such as interleukin 1β (IL-1β), tumor necrosis factor (TNF), and IL-6 \[[@REF16]\]. COVID-19 induces mast cell proliferation within the respiratory submucosa \[[@REF17]\] and activates the NF-kB pathway \[[@REF18]\], further increasing the inflammatory response. As a result, individuals with COVID-19 present with fever, cough, and SOB. Severe infection can progress to acute respiratory failure and vascular thrombosis. COVID-19 is additionally correlated with acute cardiac injury and increased troponin I levels \[[@REF19]\].

DOXY, an analog of tetracycline, is lipophilic and can also easily penetrate the lung epithelium \[[@REF20]\]. Chemically modified tetracyclines (CMTs) can also induce apoptosis of mast cells \[[@REF21]\]. The drug downregulates inflammatory markers demonstrated to have a role in COVID-19 pathophysiology. Evidence shows that DOXY downregulates the expression of DPP4 through the inhibition of the NF-kB pathway \[[@REF22]\], impeding the virus's ability to enter cells and consequently decreasing the viral load. Along with its anti-inflammatory and immunomodulatory properties, DOXY is considered to be cardioprotective. During reperfusion after myocardial injury, matrix metalloproteinases-2 (MMP-2) are released. DOXY's inhibition of the MMP-2 pathway rescues left ventricular function \[[@REF23]\]. As a result, in patients with acute ST-segment elevation myocardial infarct (STEMI) and left ventricular dysfunction, DOXY reduces adverse left ventricular remodeling \[[@REF24]\]. DOXY's cardioprotective characteristics may improve clinical recovery in COVID-19 patients with acute myocardial injury.

DOXY is also thought to have antiviral activity. In-vitro assays of cultured cells inoculated with the dengue virus suggest that DOXY inhibits the virus's serine protease, disrupting viral replication, and viral entry into cells \[[@REF25]\]. Another study demonstrates that when cells infected with murine retrovirus were treated with DOXY, there was a 70% decrease in retroviral load \[[@REF26]\]. Tetracyclines can potentially treat other viral infections as well, such as viral encephalitis, West Nile virus, and human immunodeficiency virus (HIV) \[[@REF27]\]. Further research reveals that elevated levels of intracellular zinc inhibit viral replication of COVID-19 \[[@REF28]\] and that DOXY facilitates this inhibition by acting as a zinc ionophore, transporting, and increasing intracellular concentrations of zinc. Recently, a study demonstrated that in-vitro, DOXY itself has antiviral activity against COVID-19 at a concentration of 5.6 µM \[[@REF29]\].

DOXY has anti-inflammatory, immunomodulatory, cardioprotective, and antiviral properties. No observational study has yet been done using an early regimen of DOXY to treat moderate to severe high-risk COVID-19 patients in an LTCF. This case series demonstrates that early DOXY treatment in a non-hospital environment has good clinical recovery (85%, n=76), minimized hospital transfers (3%, n=3), and reduced death (11%, n=10).

A limit to this study is that there was no control group. We thus compared the data from this population to that of a similar reference patient population in an LTCF in Washington. This study performed an epidemiological investigation regarding 129 confirmed cases of COVID-19. Of the 129 confirmed cases, 63% (n=81) were LTCF residents (median age = 81 years, range = 54-100 years), 26% (n=34) were healthcare workers (median age = 42.5 years, range = 22-79 years, and 11% (n=14) were visitors (median age = 62.5 years, range = 52-88 years). Fifty-six point eight (56.8%) LTCF residents, 35.7% visitors, and 5.9% of healthcare personnel were hospitalized. Comorbidities among LTCF residents included HTN (69.1%), cardiac disease (56.8%), diabetes (37%), obesity (33%), and pulmonary disease (32.1%). Of the total population, 65.1% (n=84) were women. While no deaths occurred among staff members, 27.2% of LTCF residents and 7.1% of visitors died \[[@REF30]\]. Comparing this study\'s data to our data using naive indirect comparison, early DOXY treatment may reduce hospital transfers and decrease mortality.

Conclusions
===========

In this cohort of high-risk LTCF residents with moderate to severe COVID-19 infections who were treated with an early course of DOXY, improvement in oxygen saturation and resolution of fever were factors associated with lower mortality. The median time of all deaths in these high-risk patients was within the first 10 days in the course of illness. In the majority of our cohort, early initiation of DOXY treatment was associated with improved clinical outcomes, decreased hospitalizations, and decreased mortality. Larger randomized control trials are required to study the effect of DOXY treatment in moderate to severe COVID-19 infections.
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